CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Evaluation of central nervous system involvement in patients undergoing chimeric antigen receptor-engineered T-cell therapy by magnetic resonance imaging.
Evaluation of central nervous system involvement in patients undergoing chimeric antigen receptor-engineered T-cell therapy by magnetic resonance imaging.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
嵌合抗原受体工程化(CAR)T细胞疗法是治疗侵袭性血液系统恶性肿瘤的有效免疫疗法。然而,它可能导致并发症,如免疫效应细胞相关神经毒性综合征(ICANS),或与这些患者免疫抑制状态相关的并发症。在此背景下,影像学的作用至关重要,有助于ICANS的诊断并排除其他潜在诊断,如中枢神经系统感染。本文呈现两例病例以说明这一临床问题。病例1:描述一名38岁弥漫性大B细胞淋巴瘤患者,在CAR-T 细胞治疗后发生ICANS。MRI显示白质脑病征象。病例2涉及一名57岁套细胞淋巴瘤患者,在CAR-T 治疗后出现神经系统症状——临床提示ICANS。MRI显示提示边缘性脑炎的征象。这两例病例强调了CAR-T 细胞治疗后临床实践中MRI的重要性,突显了MRI在伴有神经精神症状患者并发症诊断中的作用。
Chimeric antigen receptor-engineered (CAR) T-cell therapy is an effective immunotherapy for aggressive hematologic cancers.
However, it can lead to complications such as immune effector cell-associated neurotoxicity syndrome (ICANS), or complications related to the immunosuppressive status of these patients. The role of imaging in this context is essential to help in ICANS diagnosis and to rule out other potential diagnosis, such as central nervous system infections. Two cases are presented to illustrate this clinical problem. CASE 1: describes a 38-year-old patient with diffuse large B-cell lymphoma who developed ICANS after CAR T-cell therapy.
MRI revealed signs of leukoencephalopathy. Case 2 involves a 57-year-old patient with mantle-cell lymphoma who presented neurologic symptoms -clinically suggestive of ICANS- after CAR-T therapy. MRI showed signs indicative of limbic encephalitis. These two cases highlight the importance of MRI in clinical practice after CAR T-Cell Therapy underscoring the role of MRI in the diagnosis of complications in patients with neuropsychiatric symptoms.
MEMBER ACCOUNT
登录成功会直接打开下一页。